One area of focus is long-term studies that follow patients over several years
The glp-1 monitoring tools for home use guide covers practical home monitoring options
Drug expiry debate: the myth and the reality - African Health Science Assessment report: Ozempic - European Medicines Agency Exploring beyond numeric weight loss: The metabolic effects of semaglutide - Clinical nutrition ESPEN Expiration Dates - FDA Insulin Storage: A Critical Reappraisal - Journal of Diabetes Science & Technology Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages - Clinical Diabetes, American Diabetes Association APIC position paper: Safe injection, infusion, and medication vial practices in health care - American Journal of Infection Control
Oral semaglutide (Rybelsus) already exists for the diabetes indication at lower doses, and higher-dose oral formulations for weight management are in late-stage development
Weight loss effects vary between individuals and doses
Three HCC tiers for diabetes (CMS-HCC V28, current as of 20252026): HCC 36: Diabetes with acute complications (highest risk weight) HCC 37: Diabetes with chronic complications: neuropathy, nephropathy, retinopathy, circulatory problems HCC 38: Diabetes without complications (E11.9), lowest risk weight Note: Older resources may reference V24 numbers (HCC 17, 18, 19)
